Pfizer Reports Updated Data from Phase III Study on Ibrance


Category: topSource: redinewsDec 7th, 2017

Bristol-Myers Reports Data from Opdivo Combination Studies

Bristol-Myers (BMY) presented multiple data from Opdivo combination studies. Bristol-Myers Squibb Company BMY announced updated results from the multi-arm phase Ib study, CheckMate -012, evaluating the safety and tolerability (primary endpoints.....»»

Category: topSource: zacksDec 6th, 2016

Juno Reports Additional Data on CAR-T Therapy, Shares Drop

Juno (JUNO) releases additional results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate, JCAR017. Juno Therapeutics, Inc. JUNO along with partner Celgene Corporation CE.....»»

Category: worldSource: nytDec 12th, 2017

Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug

Bristol-Myers Squibb Company (BMY) announced positive data from an ongoing phase II study on leukemia drug Sprycel in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone for two years. .....»»

Category: worldSource: nytDec 12th, 2017

Gilead (GILD) Posts Updated Data on CAR-T Therapy Yescarta

Gilead (GILD) announced follow-up data from a phase II study, on its CAR-T therapy, Yescarta for treatment of refractory large B-cell lymphoma. Gilead Sciences Inc. GILD announced long-term follow-up.....»»

Category: dealsSource: nytDec 11th, 2017

Incyte (INCY) Reports Phase III Follow-Up Data for Jakafi

Incyte (INCY) announced new 208-week (4-year) follow-up data from the phase III RESPONSE study of Jakafi. Incyte Corporation INCY announced a new 208-week (4-year) follow-up data from the phase III RESPONSE study of Jakafi. The .....»»

Category: worldSource: nytDec 11th, 2017

Roche Reports Tecentriq/Avastin Lung Cancer Study Data

Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer. Roche’s RHHBY member Genentech, annou.....»»

Category: personnelSource: nytDec 7th, 2017

Jounce Therapeutics Reports Third Quarter 2017 Financial Results

- Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC study in 1H 2018 - - Strengthen leadership team and board with key new appointmen.....»»

Category: earningsSource: benzingaNov 13th, 2017

46 Stocks Moving In Wednesday"s Mid-Day Session

Gainers OncoSec Medical Inc (NASDAQ: ONCS) shares climbed 49.6 percent to $1.87 after the company disclosed positive updated long-term follow-up data from its Phase 2 OMS I-102 combination study of ImmunoPulse® IL-12 and pembrolizumab. read more.....»»

Category: blogSource: benzingaNov 8th, 2017

Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda

Incyte Corporation (INCY) announced new and updated data from the ongoing phase I/II ECHO-202 trial on pipeline candidate epacadostat with Keytruda. Incyte Corporation INCY announced that the European S.....»»

Category: smallbizSource: nytSep 1st, 2017

Jounce Therapeutics Reports Second Quarter 2017 Financial Results

- Presented Phase 1 data from ICONIC study of JTX-2011 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting - - Initiated Phase 2 portion of ICONIC study evaluating JTX-2011 in advanced solid tumors in.....»»

Category: earningsSource: benzingaAug 9th, 2017

Ironwood (IRWD) Reports Positive Data on Reflux Candidate

Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease. Ironwood Pharmaceuticals, Inc. IRWD announced positive top-l.....»»

Category: topSource: zacksJul 21st, 2017

Paratek Antibiotic Candidate"s Phase III Data Favorable

Paratek Pharmaceuticals, Inc. (PRTK) announced positive results from a phase III study (OASIS-2) comparing its antibiotic candidate omadacycline to Pfizer Inc.'s (PFE) Zyvox for the treatment of acute bacterial.....»»

Category: topSource: zacksJul 18th, 2017

Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti

Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology .....»»

Category: topSource: zacksJun 27th, 2017

Incyte Provides Updated Data on Cancer Combination Therapies

Incyte along with partner Bristol-Myers Squibb announced updated data from phase I/II study, ECHO-204, evaluating epacadostat in combination with Opdivo for the treatment of squamous cell carcinoma of the head and neck and melanoma. Incyte .....»»

Category: topSource: zacksJun 6th, 2017

Pfizer Provides Final Update on Phase II Talazoparib Study

Pfizer Inc. (PFE) announced data from its phase II study, ABRAZO, which is evaluating talazoparib in advanced breast cancer patient.....»»

Category: topSource: zacksJun 5th, 2017

Matinas BioPharma Reports 2016 Financial Results and Provides Corporate Update

– 2016 marked by significant corporate and clinical advancements – – Recently announced positive topline data from initial study in Phase 1 program for MAT2501 – – On track to report interim Phase 2 data of M.....»»

Category: earningsSource: benzingaApr 3rd, 2017

Heron Therapeutics reports topline data from Phase 2 HTX-011 study

See the rest of the story here. provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 4th, 2017

Synergy Reports Positive Top-Line Phase III Data on IBS Drug

Synergy Pharmaceuticals announced positive top-line data from a pivotal phase III study evaluating the efficacy and safety of its investigational drug, plecanatide, for the.....»»

Category: topSource: zacksDec 27th, 2016

Loxo Oncology reports updated Phase 1 data on LOXO-101

See the rest of the story here. provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 18th, 2016